Skip to main content
Up to 53% offSee the plans

News | Stocks | Iran

Exir Pharmaceutical (EXIR) Six-Month Profit Rises 4.5-Fold to 34,165 Billion Rials, More Than Twice All of Fiscal 1404

Sahmino Newsroom | 20 November 2026 | 15 hours ago

EXIRup3.0%34,960rials18 November

In its audited standalone income statement for the six months to 31 Shahrivar 1405 (22 September 2026), filed on Codal on 18 November 2026 (27 Aban), Exir Pharmaceutical (EXIR) reported operating revenue of 83,345 billion rials, up 194% from 28,373 billion rials in the same period a year earlier (a restated comparative column). Gross profit grew 290% to 50,338 billion rials and the gross margin rose from 45.5% to 60.4%.

Operating profit was 47,914 billion rials (up 300%) and net profit 34,165 billion rials, against 7,523 billion rials a year earlier. Earnings per share rose from 816 to 3,711 rials. That net profit equals 220% of the full fiscal 1404 profit (15,498 billion rials), and the six-month revenue equals 144% of that year's revenue (57,933 billion rials). Current-year income tax was 10,293 billion rials, finance costs were 3,742 billion rials, and the company's capital is 9,217 billion rials.

Reference:CodalThe original report

Sahmino context

What the prices have done since this story was published, and what Sahmino wrote around it

More from this market